International survey of antibiotic dosing and monitoring in adult intensive care units

Table 2 TDM utilization according to antibiotic

Characteristic	Target	n (%)
Vancomycin TDM
PK/PD target II (n = 380)	AUC/MIC target 400–600 mg·h/L	80 (21)
	Trough target	300 (79)
	10–15 mg/L	36 (9)
	12–18 mg/L	31 (8)
	15–20 mg/L	183 (48)
	20–25 mg/L	40 (11)
	Other	10 (3)
PK/PD target CI (n = 69)	AUC/MIC target 400–600 mg·h/L	9 (13)
	Css target	60 (87)
	20–25 mg/L	45 (65)
	15–20 mg/L	11 (16)
	Other	4 (6)
Piperacillin/tazobactam TDM
PK/PD target (n = 258)	100% fT > 4xMIC	59 (23)
	100% fT > MIC	92 (36)
	50% fT > 4xMIC	46 (18)
	50% fT > MIC	33 (13)
	AUC/MIC	11 (4)
	Unsure or other	17 (7)
Meropenem TDM
PK/PD target (n = 204)	100% fT > 4xMIC	52 (25)
	100% fT > MIC	57 (28)
	50% fT > 4xMIC	27 (13)
	50% fT > MIC	29 (14)
	AUC/MIC	9 (4)
	Unsure or other	18 (9)
Aminoglycoside TDM
PK-PD target (n = 385)	100% fT > MIC	24 (6)
	AUC/MIC	65 (17)
	CMax/MIC	166 (43)
	Unsure	130 (34)
1^st TDM sample (n = 387)	Peak	144 (37)
	Trough	205 (53)
	Other	41 (11)
Peak and trough sample taken? (n = 144)	Yes	108 (75)
	No	36 (25)

TDM, therapeutic drug monitoring; PK, pharmacokinetics; PD, pharmacodynamics; II, intermittent infusion; AUC, area under the curve; MIC, minimum inhibitory concentration; CI, continuous infusion; EI, extended infusion; Css, concentration at steady state; fT, free time; CMax, concentration maximum; n, number; %, percentage

ISSN: 1364-8535